Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Trastuzumab Imbotolimod · BDC-1001

Antibody-drug conjugate · Immune activation, directed at HER2 (ERBB2), TLR7 and TLR8 · developed by Bolt Biotherapeutics

Phase 2 Most advanced trial (none active)
BOLT Developer
1 Registered trials

What is Trastuzumab Imbotolimod?

Trastuzumab imbotolimod is an immune-stimulating antibody conjugate in which a trastuzumab-based antibody binds HER2 on tumor cells and carries a TLR7/8 dual agonist payload. The TLR7/8 agonist activates dendritic cells in the tumor microenvironment to stimulate antitumor immune responses. It is studied in HER2-positive and metastatic breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
BDC-1001
Drug type
Antibody-drug conjugate
Targets
HER2 (ERBB2), TLR7, TLR8
Mechanism
Immune activation, directed at HER2 (ERBB2), TLR7 and TLR8
Pathways
TLR7/8-mediated innate immune signaling, dendritic cell maturation and activation, cytotoxic T-lymphocyte and B-lymphocyte responses
Therapy area
Oncology
Developer
Bolt Biotherapeutics, Inc. (BOLT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
LNG8RG3NMF

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05954143 Phase 2 Metastatic Breast Cancer Terminated BOLT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HER2-positive Breast CancerMetastatic Breast Cancer

Other drugs acting on ERBB2 / TLR7 / TLR8

More from Bolt Biotherapeutics

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the BOLT page.

Follow BOLT, the company behind Trastuzumab Imbotolimod

See BOLT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BOLT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.